Sensorion Appoints Fred Chereau as CEO
Sensorion, a pioneering clinical-stage biotechnology company specialising in the development of novel therapies to restore, treat and prevent hearing loss disorders, on May 18th announced the appointment of Fred Chereau as Chief Executive Officer (CEO), effective June 1, 2026. Fred brings more than 30 years of leadership and operational experience across the biotechnology, pharmaceutical, and medical […]
STEMCELL Technologies Acquires Cellular Highways Ltd
STEMCELL Technologies, one of Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where […]
Incyte finalizes the acquisition of Escient Pharmaceuticals
Incyte yesterday announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders. “The acquisition of Escient and its first-in-class oral MRGPR antagonists bolsters our Inflammation and Autoimmunity portfolio and our commitment to creating innovative solutions that address […]
Matica Bio designates Paul Kim as CEO
Matica Biotechnology, Inc., a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), yesterday announced the appointment of Paul Kim as chief executive officer (CEO). As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and […]
Synplogen collaborates with Ginkgo Bioworks
Synplogen Co., a synthetic biology startup spun out of Kobe University’s Graduate School of Science, Technology and Innovation that provides custom DNA synthesis and Gene Therapy Biofoundry services, and Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding Memorandum of Understanding (“MOU”). Together, Synplogen […]